Group One Trading’s Marker Therapeutics MRKR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$231 Hold
178
﹤0.01% 7387
2025
Q4
$265 Hold
178
﹤0.01% 7864
2025
Q3
$159 Hold
178
﹤0.01% 8225
2025
Q2
$272 Hold
178
﹤0.01% 7718
2025
Q1
$219 Hold
178
﹤0.01% 7368
2024
Q4
$554 Hold
178
﹤0.01% 6993
2024
Q3
$502 Hold
178
﹤0.01% 6391
2024
Q2
$967 Hold
178
﹤0.01% 6368
2024
Q1
$765 Hold
178
﹤0.01% 6686
2023
Q4
$979 Hold
178
﹤0.01% 6989
2023
Q3
$819 Hold
178
﹤0.01% 7252
2023
Q2
$552 Hold
178
﹤0.01% 7354
2023
Q1
$126 Sell
178
-111
-38% -$264 ﹤0.01% 7022
2022
Q4
$761 Sell
289
-237
-45% -$818 ﹤0.01% 6892
2022
Q3
$2K Buy
526
+210
+66% +$771 ﹤0.01% 7170
2022
Q2
$1K Sell
316
-2,727
-90% -$9.07K ﹤0.01% 7584
2022
Q1
$13K Buy
3,043
+158
+5% +$903 ﹤0.01% 7054
2021
Q4
$27K Buy
+2,885
New +$38.3K ﹤0.01% 6786
2020
Q2
Sell
-76
Closed -$1.66K 6031
2020
Q1
$1K Sell
76
-505
-87% -$12.9K ﹤0.01% 5087
2019
Q4
$17K Sell
581
-790
-58% -$28.7K ﹤0.01% 4418
2019
Q3
$70K Buy
1,371
+618
+82% +$36.5K ﹤0.01% 3800
2019
Q2
$60K Buy
+753
New +$44.7K ﹤0.01% 3676

Other funds holding MRKR

Group One Trading's MRKR Position: Q1 2026 in Review

Group One Trading held its Marker Therapeutics (MRKR) position steady in Q1 2026 at 178 shares worth $231. The position accounts for ﹤0.01% of the portfolio, ranked #7387.

Group One Trading first reported a position in MRKR in Q2 2019 and has held it in 22 quarters since. The position peaked at $70K in Q3 2019. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

  • Group One Trading held 178 shares of Marker Therapeutics worth $231 as of Q1 2026.
  • Group One Trading left its Marker Therapeutics share count unchanged in Q1 2026.
  • Marker Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7387 holding.
  • Group One Trading first reported a position in Marker Therapeutics in Q2 2019 and has held it in 22 quarters since.
  • Group One Trading's Marker Therapeutics position peaked at $70K in Q3 2019.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.